202 related articles for article (PubMed ID: 20828417)
1. Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco.
Boutayeb S; Boutayeb A; Ahbeddou N; Boutayeb W; Ismail E; Tazi M; Errihani H
Cost Eff Resour Alloc; 2010 Sep; 8():16. PubMed ID: 20828417
[TBL] [Abstract][Full Text] [Related]
2. First data on direct costs of lung cancer management in Morocco.
Tachfouti N; Belkacemi Y; Raherison C; Bekkali R; Benider A; Nejjari C
Asian Pac J Cancer Prev; 2012; 13(4):1547-51. PubMed ID: 22799364
[TBL] [Abstract][Full Text] [Related]
3. Direct costs of cervical cancer management in Morocco.
Berraho M; Najdi A; Mathoulin-Pelissier S; Salamon R; Nejjari C
Asian Pac J Cancer Prev; 2012; 13(7):3159-63. PubMed ID: 22994727
[TBL] [Abstract][Full Text] [Related]
4. Does Trastuzumab Offer Good Value for Money for Breast Cancer Patients with Metastasis in Indonesia?
Kristin E; Endarti D; Khoe LC; Pratiwi WR; Pinzon RT; Febrinasari RP; Yasmina A; Nugrahaningsih DAA; Taroeno-Hariadi KW; Karsono R; Sudarsa IW; Prenggono MD; Herlinawaty E; Komaryani K; Hidayat B; Nadjib M
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2441-2447. PubMed ID: 35901352
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
11. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
Leung W; Kvizhinadze G; Nair N; Blakely T
PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage
Gershon N; Berchenko Y; Hall PS; Goldstein DA
Cost Eff Resour Alloc; 2019; 17():5. PubMed ID: 30867655
[TBL] [Abstract][Full Text] [Related]
13. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
[TBL] [Abstract][Full Text] [Related]
14. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
16. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
17. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
Martins SJ; Yamamoto CA
Rev Assoc Med Bras (1992); 2008; 54(6):494-9. PubMed ID: 19197525
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
